These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36505860)

  • 1. NSCLC patients with rare
    Wang H; Yu Q; Shi L; Hou Q; Dan L; Liang C; Hong X; Zhao Y; Ning R
    Front Oncol; 2022; 12():1054593. PubMed ID: 36505860
    [No Abstract]   [Full Text] [Related]  

  • 2. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With
    Wei Y; Jiang B; Liu S; Zhang Z; Fang W; Yang Y; Li X; Zhao J; Zhao H
    JTO Clin Res Rep; 2021 Jul; 2(7):100193. PubMed ID: 34590038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
    Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
    Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Patients with
    Sanchis-Borja M; Guisier F; Swalduz A; Curcio H; Basse V; Maritaz C; Chouaid C; Auliac JB
    Onco Targets Ther; 2024; 17():439-448. PubMed ID: 38836187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking.
    Yu N; Xu Y; Wang X; Sun C; Qiu S; Guo Y; Bai M; Huang Y; Ma K
    Oncologist; 2021 Nov; 26(11):e1903-e1908. PubMed ID: 34396638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
    He SY; Lin QF; Chen J; Yu GP; Zhang JL; Shen D
    World J Clin Cases; 2021 Feb; 9(6):1329-1335. PubMed ID: 33644199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
    Kunimasa K; Sugimoto N; Tamiya M; Inoue T; Kawamura T; Kanzaki R; Okami J; Nishino K
    Invest New Drugs; 2022 Oct; 40(5):1137-1140. PubMed ID: 35657573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
    Zhang Y; He B; Zhou D; Li M; Hu C
    Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.
    Zhang C; Lin L; Zuo R; Wang Y; Chen P
    Thorac Cancer; 2020 Sep; 11(9):2743-2748. PubMed ID: 32776462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.
    Huang Y; Xu C; Sun Y; Wang W; Li X; Liao J; Pang L; Zeng L; Li J; Wang X; Zhang Q; Xie Z; Xiao L; Gan J; Fang W
    Lung Cancer; 2022 Oct; 172():117-123. PubMed ID: 36063602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
    Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
    Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
    Ishii H; Azuma K; Sakai K; Naito Y; Matsuo N; Tokito T; Yamada K; Hoshino T; Nishio K
    Sci Rep; 2020 Jan; 10(1):691. PubMed ID: 31959859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of afatinib in an NSCLC patient with
    Nozaki K; Watanabe S; Nishio K; Sakai K; Kikuchi T
    Transl Cancer Res; 2022 Jan; 11(1):295-298. PubMed ID: 35261905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
    Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
    Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.